Introduction
In the United States, breast cancer is the most common cancer diagnosed among adolescent and young adult women (AYA, ages 15-39 years), 1 accounting for over 12,000 new cases in 2015. 2 With recent improvements in breast cancer survival in young women, 3 there is a growing number of young breast cancer survivors who face unique survivorship concerns related to the impact of a cancer diagnosis and treatment on reproductive outcomes. Increases in cancer survival coincide with continued trends toward a delayed age at first birth among U.S. women, 4 and many women with breast cancer may not have completed childbearing by the time of their diagnosis. Though the importance of fertility counseling in younger cancer patients is increasingly recognized, 5 there remains a paucity of population-based evidence on the incidence of live birth and birth outcomes among women with a history of breast cancer. Pregnancy after breast cancer does not appear to reduce survival or increase risk of cancer recurrence. [6] [7] [8] However, physicians generally recommend that breast cancer patients wait at least 2 years before becoming pregnant. For women with hormone-responsive tumors receiving endocrine therapy, the recommended wait may be longer, as pregnancy is not recommended during the 5-to 10-year course of tamoxifen. These delays mean breast cancer survivors may be attempting to conceive at older ages when fertility is reduced and the risk of adverse birth outcomes is higher. In addition, exposure to certain cancer treatments, particularly alkylating agent-based chemotherapies, may lead to decreased ovarian reserve, 9 further threatening future fertility in women receiving these therapies. Although embryo and oocyte cryopreservation are accepted methods for fertility preservation in post-pubertal female cancer patients about to receive gonadotoxic therapies, 5 these strategies remain underprescribed and underutilized. 10 cancer survivors relative to age-matched women in the general population. Other reports suggest that those who do give birth after breast cancer may have an increased risk of low birth weight and preterm deliveries compared to women without cancer. [14] [15] [16] [17] [18] However, variation in these outcomes according to factors such as hormone receptor status and endocrine therapy use has not been previously explored.
Using population-based data from North Carolina, the aims of our study were to (1) describe the incidence of live birth after an AYA breast cancer diagnosis, and (2) compare the prevalence of adverse birth outcomes between AYA breast cancer survivors and the general population. We also evaluated potential variation in these outcomes according to demographic, tumor and treatment characteristics.
Material and Methods
We identified 4,978 women with a first primary diagnosis of breast cancer at ages 15-39 years between January 1, 2000 and December 31, 2013 in the North Carolina Central Cancer Registry (CCR). Breast cancer diagnoses were defined by the primary site codes C500-C509 and histology codes 8010-8589, using AYA-specific recodes of the International Classification of Diseases for Oncology (ICD-O-3) definitions. 19 To estimate the cumulative incidence of live birth after a breast cancer diagnosis, we included the first postdiagnosis birth to women with breast cancer where the total recorded gestational length, as indicated on the birth certificate, occurred after the woman's date of breast cancer diagnosis. Thus births to women diagnosed during pregnancy were not considered events. For women who were diagnosed with breast cancer during pregnancy (N 5 91), we included the first additional live birth that was conceived after the breast cancer diagnosis. Multiple births (i.e., twins and triplets) were counted as a single event.
For analyses comparing birth outcomes between women with and without an AYA breast cancer diagnosis, we identified all singleton live births to women with breast cancer that had a gestational age of 20 weeks and a birthweight of 500 g and occurred after the date of the mother's breast cancer diagnosis. Births to women diagnosed with breast cancer during pregnancy were excluded (N 5 91); however, subsequent births to these women that also occurred during the study period were included (N 5 6). For each included birth to women with breast cancer (N 5 338), we randomly sampled 20 births from 1,767,474 live births to women without a recorded cancer diagnosis, with frequency matching on year of delivery and maternal age. Outcomes included preterm birth (<37 weeks gestation), low birth weight (<2,500 g), small-for-gestational age (SGA) and Cesarean delivery. SGA was defined as a birthweight below the 10th percentile of infants of the same sex and gestational age, according to the nomogram published by Oken et al.
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Statistical analysis
Cox proportional hazards models were used to estimate cause-specific hazards ratios (HR) and 95% confidence intervals (CI) for first postdiagnosis live birth according to demographic, tumor and treatment characteristics among women with breast cancer. Person-time began on the date of breast cancer diagnosis and ended on the date of first postdiagnosis live birth, death, age 46, or December 31, 2014, whichever occurred first. The assumption of proportional hazards was evaluated by visual inspection of log-log plots. This evaluation suggested evidence of non-proportional hazards in analyses according to ER status and endocrine therapy; thus these HR estimates should be interpreted as time-averaged summary measures. To estimate the cumulative incidence of live birth at 5 and 10 years after diagnosis, we used the Fine and Gray method 23 with death as a competing risk. Cancer Epidemiology Table 1 . Characteristics of AYA breast cancer survivors and estimated cumulative incidence and hazard ratios (HR) for postdiagnosis live births (Continued) 
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Multiple pregnancies per woman were included in analyses of birth outcomes. Prevalence ratios, comparing births to women with and without cancer, were estimated using Poisson regression models fitted with generalized estimating equation methods. Multivariable models were adjusted for maternal age (<30, 30-34, 351), race (White, Black, other), education (high school or less, some college, Bachelor's degree or higher), marital status (married, unmarried), smoking during pregnancy (any, none) and previous live births (0, 1, 2, 31). Due to a change in the format of the birth certificate in 2010, all 2010 births were missing information on Cesarean delivery, mother's education and smoking during pregnancy. Therefore births occurring in 2010 were excluded from analyses of Cesarean deliveries, and all multivariable models of birth outcomes.
We used published general population birth rates for North Carolina in 2013 24 to compare observed birth rates among AYA breast cancer survivors to expected birth rates among women without cancer. Within each stratum of age and race/ethnicity, the number of expected births was calculated by multiplying the general population birth rate by the number of breast cancer survivors in our cohort who were alive at that age at the end of 2013. The standardized birth ratio (SBR) was then calculated as the ratio of observed to expected births, summed across strata of age and race/ethnicity. Confidence intervals were calculated using Fisher's exact methods.
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Results
The 4,978 AYA breast cancer survivors in our cohort had an average age at diagnosis of 35.0 years (SD 5 3.7) and contributed a total of 29,215 person-years of follow-up for first postdiagnosis live birth (median 5 6.0 years/woman). A total of 293 women had at least one live birth after diagnosis, corresponding to an overall cumulative incidence of 5% and 8% at 5 and 10 years postdiagnosis, respectively (Table 1 ). In 2013, the age-and race-adjusted birth rate among AYA breast cancer survivors was significantly lower than that in the general population (SBR (Table 1 ). In analyses restricted to women with localized or regional disease, corresponding HRs for chemotherapy with and without radiation were 0.70 (95% CI: 0.48-1.04) and 0.82 (95% CI: 0.56-1.21), respectively. Hazard ratios for live birth did not vary substantially by race.
Compared to ER-positive, women with ER-negative breast cancer were 1.31 times as likely to have a live birth (HR 5 1.31; 95% CI: 0.97-1.78); this was largely driven by the lower cumulative incidence of birth among ER-positive women over the first approximately 8 years of follow-up (Fig.  1) . However, at 10 years, the cumulative incidence of live birth was 10% in both groups. Among women with ER- positive tumors, those receiving endocrine therapy were less likely to have a live birth over most of the study period than women not receiving endocrine therapy (HR 5 0.47; 95% CI: 0.31-0.71), though the cumulative incidence among endocrine therapy users actually exceeded that in non-users by 10 years after diagnosis (11% vs. 10%) (Fig. 2) .
Analyses of birth outcomes compared 338 singleton births to breast cancer survivors to 6,760 births to women without cancer. The average maternal age at delivery in both groups was 35 years (SD 5 4) ( Table 2) . Overall, the proportions of preterm birth, low birth weight, SGA and Cesarean delivery, were similar for women with and without a breast cancer history (Tables 3 and 4) . In subgroup analyses, PRs were modestly elevated for women with invasive breast cancer relative to the noncancer cohort for both preterm birth (PR 5 1.29; 95% CI: 0.92-1.81) and low birth weight (PR 5 1.29; 95% CI: 0.89-1.87), though the prevalence of SGA did not differ substantially between groups (PR 5 1.08; 95% CI: 0.75-1.56) ( Table 4 ). For women with in situ breast cancer, the small number of outcomes precluded meaningful analyses within this group.
ER-positive breast cancer was not associated with a higher prevalence of any of the four outcomes evaluated relative to the noncancer cohort. However, births to women with ERnegative disease were more likely to be preterm (PR 5 1.84; 95% CI: 1.11-3.06) and low birth weight (PR 5 2.51; 95% CI: 1.53-4.12), even after adjustment for maternal age, race and other covariates. PRs did not differ greatly according to endocrine therapy or chemotherapy for most outcomes. However, a suggestive though nonsignificant increase in SGA was identified among births to women treated with chemotherapy relative to the noncancer cohort (PR 5 1.25; 95% CI: 0.86, 1.83). In general, PRs among births occurring 5 or more years after diagnosis were greater than among those occurring <5 years from diagnosis, but estimates were relatively imprecise.
Discussion
With trends toward delayed childbearing in the U.S., and increases in breast cancer survival in young women, there is an increasing number of reproductive-age breast cancer survivors who may wish to have children in the years following diagnosis and treatment. In this population-based study, we found that the birth rate among AYA breast cancer survivors was about 40% of that in the general population of North Carolina in 2013. Among AYAs with breast cancer, postdiagnosis live births were less common after a diagnosis of regional or distant stage disease and after treatment with chemotherapy. Compared to women with ER-negative tumors, those with ER-positive tumors had a lower cumulative incidence at 5 years, but not at 10 years, after diagnosis. After accounting for maternal age and other risk factors, we observed modest increases in preterm birth and low birth weight among births to women with invasive breast cancer relative to the noncancer comparison cohort, consistent with previous reports of women who conceived after a breast cancer diagnosis. 17, 18 Our overall estimates of cumulative incidence are within the range of those reported in previous population-based studies of breast cancer survivors in developed countries. [11] [12] [13] 26, 27 However, our study reflects more recent Cancer Epidemiology diagnoses and treatment protocols and is, to date, the first to focus on AYAs and to evaluate characteristics such as ER status and endocrine therapy. In a study from Canada, the 10-year cumulative incidence of childbirth was 23% among breast cancer survivors diagnosed at ages 20-34 during 1992-1999. 11 In addition to the difference in age range, their analyses required all women to have survived at least 5 years without a recurrence. Similar studies from Northern Europe have reported postdiagnosis pregnancy proportions ranging from 1% to 6% among breast cancer patients diagnosed as early as the 1960s and 1970s and followed through the early 2000s. 12, 13, 26, 27 As expected, postdiagnosis live births in our analyses were significantly less common among women treated with chemotherapy and those with a more advanced stage of disease at diagnosis. We did not have information on the type or dose of chemotherapeutic agents. However, cyclophosphamide, an alkylating agent often used in breast cancer treatment, may cause ovarian toxicity, 28 potentially threatening future fertility. In addition to potential direct effects of chemotherapy, the time spent in active treatment may cause women to delay childbearing until older ages, when fertility is reduced. Though studies indicate that pregnancy after breast cancer does not adversely impact prognosis, psychological factors such as fear of recurrence and stress among women with more advanced disease and/or more intensive treatments may also contribute to the lower incidence of birth in these groups.
A recent meta-analysis reported that the probability of pregnancy after breast cancer among women with ERpositive tumors was about one-fourth that among women with ER-negative tumors. 29 Women with ER-positive tumors are often recommended to use 5 or more years of adjuvant endocrine therapy, and may be advised to postpone pregnancy until after therapy is completed. However, the POSI-TIVE study, an ongoing multicenter, single-arm trial, is currently investigating whether interruption of endocrine therapy to attempt pregnancy is associated with recurrence in women with hormone-responsive breast cancer. 30 In our cohort, women with ER-positive tumors were less likely to have given birth by 5 years postdiagnosis, but their cumulative incidence of childbirth matched that of women with ERnegative tumors at 10 years. This convergence likely reflects the pattern we observed among women with ER-positive tumors, in which the cumulative incidence rose more steeply between 5 and 10 years in endocrine therapy users compared to non-users. Previous U.S.-based studies have suggested that low birth weight and preterm deliveries are more common among breast cancer survivors relative to the general population. 14, 15, 18 However, among women who conceive after diagnosis, the magnitude of these associations appears to be modest. Recently, Hartnett et al. reported risk ratios (RR) of 1.3 (95% CI: 1.1-1.7) and 1.6 (95% CI: 1.3-2.0) for preterm birth and low birth weight, respectively, among postdiagnosis births to women diagnosed with invasive breast cancer at ages 20-45 in Georgia, Tennessee and North Carolina relative to a matched comparison group. The corresponding RR for SGA was 1.2 (95% CI: 0.9-1.5). 18 Likewise, in an older study from Denmark, PRs compared to women without cancer were 1.3 (95% CI: 0.7-2.2) for preterm birth and 1.2 (95% CI: 0.4-3.8) for low birth weight among women diagnosed with breast cancer before pregnancy. 17 These estimates are similar to those of our study for women with invasive breast cancer.
Our study adds information on variation in birth outcomes according to tumor and treatment characteristics. Chemotherapy was not strongly associated with either preterm birth or low birth weight among women, though the suggestive positive association with SGA in our data may warrant further investigation in larger studies. Exposure to chemotherapy may cause cardiovascular or pulmonary impairments, which could influence pregnancy outcomes through adverse effects on blood volume regulation. 31 It is not immediately clear why low birth weight and preterm deliveries were more common among women in our cohort with ER-negative tumors, even with adjustment for maternal age and race. However, these findings should be interpreted with caution, Cancer Epidemiology as they were based on a small number of outcomes and therefore are more subject to chance. It is possible that cancer recurrence and/or maternal characteristics such as comorbidities, socioeconomic status and health behaviors could partially explain these associations. This information was not available in our data, but may be an important consideration for future studies of birth outcomes according to ER status. Strengths of our study include the population-based design, and the 29,215 person-years of follow-up among almost 5,000 AYA breast cancer survivors. Some limitations should be considered. We were unable to account for the potential impact of cancer recurrence on live birth incidence or birth outcomes, as this information is not captured in registry data. We also lacked detailed information on cancer therapies, such as chemotherapeutic agents and doses. Births to women who moved out of North Carolina during the study period would also not be captured in our data. However, census data suggest that only 7% of North Carolina women moved out of state during 2000-2010. 32 Finally, our subgroup analyses of preterm birth and other birth outcomes were often limited by small sample sizes, and larger studies are needed to examine outcomes in groups defined by characteristics such as ER status.
Future reproductive outcomes are an important survivorship concern for many young women with a cancer diagnosis. Among AYA breast cancer survivors in our populationbased study, the 10-year cumulative incidence of live birth was 8% overall, and was lower among women diagnosed in their 30s, those with regional or distant stage disease, and those treated with chemotherapy. Our findings reinforce the importance of fertility counseling and the use of accepted fertility preservation strategies for breast cancer patients who may want to have children after gonadotoxic cancer treatment. For women who do become pregnant after breast cancer, our overall findings suggest that the risk of adverse birth outcomes is not greatly elevated compared to women without cancer. However, the increased prevalence of preterm birth among women with ER-negative breast cancer may warrant further investigation in larger studies.
